Kuse R, Heilmann H P, Calavrezos A, Hausmann K
Strahlentherapie. 1985 Apr;161(4):231-8.
The combination of polychemotherapy and large-field radiotherapy essentially promoted the improved total results achieved during the period of 1976 and 1982 in 272 patients with non-Hodgkin's lymphomas (NHL) of low and high malignancy. In case of centroblastic-centrocytic (cb/cc) NHL of stages II A/III A, the recurrence-free survival after radiotherapy (n = 21) could be increased by the combined method (n = 25) from 17% to 60%, and the probability of seven-year survival could be improved from 70% to 90%. All of the ten initially irradiated patients in the stages I A/II A/III A of centrocytic (cc) NHL suffered from a recurrence, whereas the development seems to be more favorable in the five patients submitted to combined treatment who had only one recurrence. The recurrence-free seven-year survival of the highly malignant NHL in stage I A/II A increased from 40% after unique radiotherapy (n = 15) to 70% after combined therapy (n = 39), the survival probability increased from 55% to 75%. Despite the partly insufficient therapy results after unique radiotherapy and polychemotherapy, the combined method has largely contributed to achieve after eight years the total survival rates of 76% for cb/cc NHL (n = 123) and of 55% for the highly malignant immunoblastic NHL (n = 57), centroblastic NHL (n = 35) and NHL with uncertain classification, whereas the cc-NHL (n = 36) hitherto has a relatively unfavorable prognosis with only 29%.
多药化疗与大野放疗相结合，从根本上推动了1976年至1982年期间272例低恶性和高恶性非霍奇金淋巴瘤（NHL）患者总体疗效的改善。对于II A/III A期中心母细胞-中心细胞（cb/cc）NHL患者，放疗后（n = 21）的无复发生存率可通过联合治疗（n = 25）从17%提高到60%，七年生存率可从70%提高到90%。中心细胞（cc）NHL的I A/II A/III A期最初接受放疗的10例患者均复发，而接受联合治疗的5例患者似乎病情发展更有利，仅有1例复发。I A/II A期高恶性NHL的无复发生存率从单纯放疗后（n = 15）的40%提高到联合治疗后（n = 39）的70%，生存率从55%提高到75%。尽管单纯放疗和多药化疗后的治疗效果部分不足，但联合治疗在很大程度上促使八年后cb/cc NHL（n = 123）的总生存率达到76%，高恶性免疫母细胞NHL（n = 57）、中心母细胞NHL（n = 35）和分类不确定的NHL的总生存率达到55%，而cc-NHL（n = 36）迄今预后相对较差，仅为29%。
